Spago Nanomedical
2.12.2021 11:01:32 CET | ACCESS Newswire | Press release
LUND, SWEDEN / ACCESSWIRE / December 02, 2021 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)
Spago Nanomedical AB (publ) today annouced that all patients have been recruited in the second dose group in the company's ongoing clinical phase I study SPAGOPIX-01 with the tumor-selective contrast agent SpagoPix (SND132D). New interim results are expected to be reported in early 2022.
A total of 6 patients with confirmed breast cancer have been included in the second dose group in the phase I study SPAGOPIX-01, which has been performed at two hospitals in Sweden. A number of adjustments to the study protocol have been made during the course of the study to, among other things, broaden the patient base and simplify the inclusion of patients. Including the 6 patients included in the first dose group, a total of 12 patients were evaluated in the study.
"It is very gratifying that we have now completed the recruitment and can start analyzing the results from the second patient group who received a higher dose of our tumor selective contrast agent SND132D", said Mats Hansen, CEO of Spago Nanomedical. "We have seen that SND132D is well tolerated by patients in lower doses, where early signals of contrast enhancement have also been shown. It will be exciting to get the results from the analysis of this dose group at the beginning of next year."
The primary endpoint of the study is to study safety at different doses of SN132D. Secondary endpoints include initially investigating how the contrast agent can enhance MRI images in clinical use in patients with solid tumors of the breast, as well as the liver and the pancreas.
Previous interim results from the study have shown a good safety profile and clear contrast in MRI images of breast tumors at the current dose. Furthermore, all images in the study showed a very good contrast in the pancreas and in the liver.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, info@fnca.se .
This information is information that Spago Nanomedical is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-02 10:34 CET.
Attachments
Second dose group fully recruited in Spago Nanomedical's phase 1 study with SpagoPix
SOURCE: Spago Nanomedical
View source version on accesswire.com:
https://www.accesswire.com/675695/Second-Dose-Group-Fully-Recruited-in-Spago-Nanomedicals-Phase-1-Study-with-SpagoPix
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Secures Technical Advisory Engagement for Nature-Based Carbon Project in Libya22.7.2026 15:00:00 CEST | Press release
Initial engagement expands the Company's international project development portfolio through technical advisory services supporting the design and optimization of a proposed nature-based carbon project. CALGARY, AB / ACCESS Newswire / July 22, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets and climate infrastructure, today announced that it has been engaged by Stream Pro Ltd, a subsidiary of Oilinvest to provide technical advisory services supporting the design and value optimization of a proposed nature-based carbon project in Libya. The engagement represents another step in Karbon-X's international project development strategy and further demonstrates the Company's expertise in the design and development of high-integrity carbon projects across emerging markets. Under the initial scope of work, Karbon-X will provide end-to-end technical support for the project's carbon design,
U.S. Polo Assn. Sponsors the 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup as Official Apparel Partner22.7.2026 13:00:00 CEST | Press release
Gaston Polo Team Claims Gold Cup Title Over Dubai Polo Team at Cowdray Park Polo Club WEST PALM BEACH, FL AND WINDSOR, UK / ACCESS Newswire / July 22, 2026 / U.S. Polo Assn.® in partnership with Brand Machine Group (BMG), its partner in the United Kingdom, proudly continued its long-standing support of the British high-goal season as the Official Apparel Partner of the 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup, held June 23 through July 19 at Cowdray Park Polo Club, known widely as "The Home of British Polo." 1) 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup Winners, Gaston Polo Team, accepting trophy on stage at Cowdray Park Polo Club 2) Gaston Polo Team attacking the ball against Dubai Polo Team in the 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup Final 3) The British Ladies Open Championship Finalists, Yaguara and Salty Polo, on stage at Cowdray Park Polo Club 4) U.S. Polo Assn.'s Experiential Merchandise
House of Hope in Bamako Continues to Provide Vital Support for Vulnerable Women in Mali in 202622.7.2026 11:00:00 CEST | Press release
BUDAPEST, HUNGARY / ACCESS Newswire / July 22, 2026 / The Gedeon Richter House of Hope centre in Bamako, Mali, continued to provide comprehensive support for vulnerable women and girls during the first half of 2026, delivering healthcare, protection, counselling, education and vocational training through its integrated programme. In the first six months of is year, nearly 50 women have been provided assistance in the center. Established through the cooperation of Gedeon Richter, the Hungary-based Close to Africa Foundation, and local partner Sini Sanuman Foundation, the House of Hope opened at the beginning of 2025 to offer shelter, gynaecological care, psychosocial and legal support, as well as educational and skills-development opportunities to women affected by violence and harmful traditional practices. Since opening its doors, the centre has supported well over a hundred women, while community outreach and awareness-raising activities have reached many more across Bamako and surro
Fermi Announces First Siemens Turbines Arrive at Port of Houston21.7.2026 22:30:00 CEST | Press release
Arrival marks an important milestone in the development of Fermi's Project Matador SGT6-5000F natural gas turbines will anchor what is expected to be the nation's largest combined-cycle natural gas project DALLAS, TX / ACCESS Newswire / July 21, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced the arrival of three Siemens Energy SGT6-5000F natural gas turbines at the Port of Houston. Together, the three turbines are rated at up to 780 megawatts in simple-cycle mode. They are bound for Fermi's Project Matador, an advanced energy and AI campus near Amarillo, Texas. This marks one of the project's largest single power-equipment moves, and it keeps Fermi well ahead of competitors in bringing gigawatt-scale power online. The delivery is the latest in a fast run of milestones. Over the past couple of weeks, Fermi selected TSK, Spain's largest power-focused EPC firm, for early works on its phase-two turbines and brought in Prim
GA-ASI and MBDA Commit to Weapons Collaboration21.7.2026 16:00:00 CEST | Press release
Companies Will Integrate SPEAR Onto MQ-9B and Gambit 6 SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and MBDA have announced a commitment to integrate the European missile-maker's SPEAR precision strike weapons onto new aircraft built by the American uncrewed aircraft manufacturer. GA-ASI President David R. Alexander and MBDA UK Managing Director Chris Allam signed a memorandum of understanding that outlined the agreement at the Farnborough International Airshow 2026. The companies will work together to ensure the MQ-9B remotely piloted aircraft and Gambit 6 collaborative combat aircraft (CCA) can carry and use the SPEAR weapons. "We've built an excellent business relationship with MBDA as part of the integration of the Brimstone missile onto the UK's Protector," said Mr. Alexander. "So, working with MBDA to enable SPEAR on our broader MQ-9B line, and our Gambit CCA, feels like a very natural extension of our partnership." Protect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom